Pattern of Obesity Among Patients with Type 2 Diabetes at a Tertiary Healthcare Center in Northern Nigeria

Ibrahim D Gezawa¹
Andrew E Uloko¹
Baffa A Gwaram¹
Daiyabu A Ibrahim¹
Ejiofor T Ugwu¹,²
Idris Y Mohammed³

¹Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria; ²Department of Medicine, Enugu State University of Science and Technology, Enugu, Enugu State, Nigeria; ³Department of Chemical Pathology, Aminu Kano Teaching Hospital, Kano, Nigeria

Purpose: Type 2 diabetes poses a major global health threat both in the developed and developing countries. Factors responsible for the soaring epidemic of T2DM in the developing countries include urbanization, ageing population, physical inactivity and increasing obesity rates. Our aim was to determine the pattern of obesity among patients with T2DM at the Aminu Kano Teaching Hospital (AKTH), Kano, Northwestern Nigeria.

Patients and methods: We consecutively recruited 220 patients with type 2 diabetes attending the diabetes clinic of AKTH for the study. Patients with Type 1 diabetes, patients who could not stand or are wheelchair bound and pregnant women were excluded from the study. A pretested questionnaire was used to collect data on socio-demographic characteristics, treatment history for diabetes and history of hypertension from each participant.

Results: Of the 220 patients recruited for this study, 97(44.1%) were men, while 123(55.9%) were women. The prevalence of generalized obesity among the study participants was 27.4%(women-30.9% vs men-22.7%, X²=4.76, p=0.190). Grades I, II and III obesity were found in 17.3%, 5.9% and 3.2% of the study participants, respectively. All the participants with grade III obesity were women. Central obesity defined by WC was detected in 111(50.5%) [20(20.6%) men and 91(73.9%) women, X²=1.97, p=0.001]. Hypertension was detected in 182(82.7%) participants [80(43.9%) men and 102(56.0%) women, X²=1.97, 0.001]. Using a cut-off of ≥0.5, abnormal WhtR was detected in 179(81.4%) [72(40.2%) men and 107(59.8%) women, X²=5.82, p=0.01], while using a cut-off of ≥0.6, abnormal WhtR was detected in 84(38.2%) participants [29 (34.5%) men and 55(65.5%) women, X²=6.38, p=0.09]. Obesity defined by WHR was recorded in 181(81.9%) [70(38.2%) men and 111(61.8%) women, X²=4.76, p=0.190). Grades I, II and III obesity were found in 17.3%, 5.9% and 3.2% of the study participants, respectively. All the participants with grade III obesity were women. Central obesity defined by WC was detected in 111(50.5%) [20(20.6%) men and 91(73.9%) women, X²=1.97, p=0.001]. Obesity defined by WHR was recorded in 182 (82.7%) participants [80(43.9%) men and 102(56.0%) women, X²=1.97, 0.001]. Using a cut-off of ≥0.5, abnormal WhtR was detected in 179(81.4%) [72(40.2%) men and 107(59.8%) women, X²=5.82, p=0.01], while using a cut-off of ≥0.6, abnormal WhtR was detected in 84(38.2%) participants [29 (34.5%) men and 55(65.5%) women, X²=6.38, p=0.09]. Hypertension was detected in 103(46.8%) participants, with a higher prevalence among women compared with men [46.3. % vs 47.4%, X²= 1.03 p=0.87].

Conclusion: The prevalence of obesity in our cohort of patients with type 2 diabetes was high. The predominant form of obesity was central obesity, which was most prevalent when indexed by WHR. The WhtR was as good as the WHR, but fared better than WC in detecting central obesity in our patients.

Keywords: type 2 diabetes, obesity, central obesity, prevalence, Nigerians

Introduction

According to the International Diabetes Federation, 463 million people are currently living with diabetes mellitus (DM) with a projected increase to 700 million by 2045.¹ The developing countries are expected to be worst hit by the epidemic with an anticipated 170% increase in DM prevalence. Type 2 diabetes (T2DM) constitutes a major global health threat.¹ Several factors are responsible for the soaring epidemic of T2DM in the developing countries. These include urbanization,
Traditionally, obesity is classified as a waist-to-height ratio cut-off point. These cut-off points identify patients with an abnormal waist circumference (WC), waist-to-hip ratio (WHR) or waist-to-height ratio (Whtr). Diabetes has a stronger association with central obesity than with generalized obesity. The prevalence of generalized obesity, as measured by body mass index (BMI) and central obesity or adiposity, defined by abnormal waist circumference (WC), waist-to-hip ratio (WHR) or waist-to-height ratio (Whtr). Diabetes has a stronger association with central obesity than with generalized obesity. The prevalence of generalized obesity among patients with type 2 diabetes across Nigeria ranges from 5.0% in Zaria, in the Northwest to 40% in Lagos in the Southwestern part of the country. Similarly, the rate for central adiposity ranged between 72%, using WC in Uyo, South-South Nigeria to 95% using WHR in Zaria, Northwestern Nigeria. However, none of the studies cited employed Whtr as a measure of central obesity. We therefore set out to determine the pattern of obesity, using established anthropometric indices, including Whtr among patients with type 2 diabetes at the diabetes clinic of Aminu Kano Teaching Hospital (AKTH), Kano, Northwestern Nigeria.

Patients and Methods

We consecutively recruited 220 patients with type 2 diabetes (T2DM) attending the diabetes clinic of AKTH for the study. Patients with type 1 diabetes, patients who could not stand or are wheelchair bound and pregnant women were excluded from the study. A pretested questionnaire was used to collect data on socio-demographic characteristics, treatment history for diabetes and history of hypertension from each participant. All participants provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki. The ethics committee of AKTH approved the study.

Physical Measurements

We measured and recorded weight, height, waist and hip circumferences on each subject. Weight was measured in kilograms (to the nearest 0.5kg) using a calibrated bathroom scale (Soehnle-Waagen GmbH & Co. KG, Wilhelm-Soehnle-Straße 2, D-71540 Murhardt/Germany) positioned on a firm horizontal surface, with the subject in light clothing and without shoes. Using a stadiometer (Soehnle GmbH & Co. KG, Germany), height was measured (in metres) to the nearest 0.1cm. Participants stood erect, without shoes and headgears, on a flat surface with the heels and occiput in contact with the stadiometer. We calculated BMI by dividing the weight (kg) by the square of the height in metres (m²). Waist circumference was measured to the nearest 0.1cm (with a non-stretchable dressmaker’s tape) at a point mid-way between the margin of the lowest rib and the iliac crest. Waist-to-height ratio was calculated by dividing WC (cm) by the height (cm).

Hip circumference (HC) was measured at the horizontal level of maximum circumference around the buttocks (posteriorly) and the pubic symphysis (anteriorly) to the nearest 0.1cm. Waist-to-hip ratio (WHR) was derived by dividing the WC (cm) by the HC (cm). Blood pressure (BP) in millimeter of mercury (mmHg) was measured to the nearest 2 mmHg, on the right arm with subjects seated quietly after 5 mins of rest with the arm and back supported, using a standard mercury sphygmomanometer with an appropriate sized arm cuff. We recorded Systolic BP (SBP) at Korotkoff Phase 1, while diastolic BP (DBP) was recorded at Phase 5.

Definition of Operational Terms

1. Body mass index (BMI) – was expressed in kg/m². Subjects with BMI <18.5 were classified as underweight and those with BMI of 18.5–24.9 were classified as having normal weight. Those with BMI of 25.0–29.9 and ≥30.0 were classified as overweight and obese, respectively.

2. Generalized obesity – obesity based on BMI ≥30.0 kg/m². Obesity was further subdivided into grade I (BMI=30.0–34.9), grade II (BMI=35.0–39.9) and grade III (BMI≥40) respectively.

3. Waist circumference (WC) – waist circumference ≥102 cm in men and ≥88 cm in women were considered abnormal. These cut-off points identify patients with the highest risk of cardiovascular disease.

4. Waist to hip ratio (WHR) – waist-to-hip ratio of ≥0.90 in men and ≥0.85 in women were considered abnormal.

5. Waist-to-height ratio (Whtr) – waist-to-height ratio of ≥0.5 in both genders was considered abnormal. A Whtr cut-off point of ≥0.6 has been shown to be effective in predicting cardiovascular disease risk in a population of patients with type 2 diabetes. This cut-off was also used in this study.
6. Central obesity (adiposity) – obesity based on abnormal cut-off values for WC, WHR, and WhtR.
7. Hypertension – hypertension was defined as SBP≥140mmHg or DBP≥90mmHg or treatment for hypertension.\textsuperscript{13}

**Laboratory Methods**

Blood samples (3mL) were collected from each participant following an overnight fast of 8–12 hrs in fluoride oxalate bottles for the estimation of fasting plasma glucose (FPG) using glucose-oxidase method.\textsuperscript{14} A second blood sample was taken 2 hr after meals for 2 hr postprandial glucose (2-HPPG) estimation.

**Statistical Analyses**

The data collected were analyzed using SPSS for Windows version 16.0 (SPSS Inc., Chicago, Illinois, USA) statistical software package. Normally distributed continuous variables were expressed as mean (SD), while non-normally distributed continuous variables were expressed as median (Q1; Q3). Distribution was assessed using the Shapiro–Wilk test. Categorical variables were expressed as proportions. Independent student’s t-test was used to compare means. Skewed continuous variables were compared using the non-parametric Mann–Whitney test. Chi-square test was used to compare proportions. Pearson’s correlation was used to determine the inter-relationship between indices of obesity. A P value of ≤0.05 was considered statistically significant.

**Results**

Out of the 220 patients recruited for this study, 97(44.1%) were men, while 123(55.9%) were women. The median (Q1; Q3) age of the participants was 53.0(18.0) years with a range of 19–94 years. The men were older with a median (Q1; Q3) age of 53.0(17.0) years compared with a median (Q1; Q3) age of 52.0(20.0) years for the women (p=0.94). The mean (SD) duration of DM was 6.1(5.9) years and was longer among men compared with women [6.9(7.3) years vs 5.3(4.5) years, p=0.04]. Table 1 shows the socio-demographic and clinical characteristics of the study subjects. Majority of our patients, 61(60.4\%) was on combination therapy with Metformin and Glibenclamide, 6.0(5.9\%) patients were on Pioglitazone combined with either Glibenclamide or Glimepiride, while 10 (9.9\%) patients were on a combination of Metformin and Glimepiride.

**Prevalence and Pattern of Obesity Among the Study Subjects**

Table 2 shows the distribution of the participants based on BMI categories. The prevalence of generalized obesity among the study participants was 27.4\% and was higher among women compared with men (30.9\% vs 22.7\%, $X^2=4.76$, p=0.19), but the difference was not statistically significant. The BMI correlated positively and significantly with WC (r=0.56, p=0.001) and WhtR (r=0.59, p=0.001). The correlation between BMI and WHR (r=0.03, p=0.696) was, however, weak and insignificant. Central obesity defined by the various indices employed in this study is shown in Figure 1.

**Prevalence of Hypertension and Its Relationship with Indices of Obesity**

The mean (SD) values of SBP and DBP of the study participants were 137.9(24.3) mmHg and 83.5(13.1) mmHg.

---

**Table 1 Sociodemographic and Clinical Characteristics of the Study Participants by Gender**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male n=97</th>
<th>Female n=123</th>
<th>Total n=220</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr – median(Q1;Q3)</td>
<td>53.0(17)</td>
<td>52(20)</td>
<td>53.0(18)</td>
</tr>
<tr>
<td>Duration of DM, yr – mean(SD)</td>
<td>6.9(7.3)</td>
<td>5.3(4.5)</td>
<td>6.1(5.9)</td>
</tr>
<tr>
<td>Weight, kg – mean(SD)</td>
<td>71.5(17.1)</td>
<td>71.4 (16.4)</td>
<td>71.4(16.7)</td>
</tr>
<tr>
<td>BMI, kg/m(^2) – mean(SD)</td>
<td>25.9(6.4)</td>
<td>28.2(6.3)</td>
<td>27.2(6.4)*</td>
</tr>
<tr>
<td>WC, cm – mean(SD)</td>
<td>90.2(15.5)</td>
<td>93.7(15.8)</td>
<td>92.2(15.7)</td>
</tr>
<tr>
<td>WHR – mean(SD)</td>
<td>0.97(0.13)</td>
<td>0.95(0.13)</td>
<td>0.96(0.13)</td>
</tr>
<tr>
<td>WhtR – mean(SD)</td>
<td>0.5(0.1)</td>
<td>0.6(0.1)</td>
<td>0.6(0.1)*</td>
</tr>
<tr>
<td>SBP, mmHg – mean(SD)</td>
<td>129.0(20.7)</td>
<td>138.9(24.4)</td>
<td>137.9(24.3)</td>
</tr>
<tr>
<td>DBP, mmHg – mean(SD)</td>
<td>81.9(12.5)</td>
<td>84.6(13.5)</td>
<td>83.5(13.1)</td>
</tr>
<tr>
<td>FPG, mmol/L – mean(SD)</td>
<td>8.7(11.8)</td>
<td>8.7(2.9)</td>
<td>7.9(2.8)</td>
</tr>
<tr>
<td>2-HPPG, mmol/L–mean(SD)</td>
<td>13.7(4.3)</td>
<td>11.9(3)</td>
<td>12.9(4.2)*</td>
</tr>
</tbody>
</table>

**Notes:** Data are mean (SD) for normally distributed continuous variables and median (Q1;Q3) for continuous variables with skewed distribution. \(^*\)Statistically significant difference (p<0.05).

**Abbreviations:** BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WhtR, waist to height ratio.
respectively. Both SBP and DBP were higher in women than in men [138.9(24.4) vs 129.0(20.7), p=0.49 and 84.6(13.5) vs 81.9(12.5), p=0.13], but the differences were not statistically significant. Hypertension was detected in 103 (46.8%) participants, with a higher prevalence among men compared with women [47.4% vs 46.3%, X²=0.02 p=0.87]. While the SBP correlated positively and significantly with all the indices of obesity viz. BMI (r=0.15, p=0.02), WC (r=0.20, p=0.02), WHR (r=0.13, p=0.04) and WhtR (r=0.21, p=0.01), the DBP had positive and significant correlation only with BMI (r=0.22, p=0.01), WC (r=0.18, p=0.01) and WhtR (r=0.20, p=0.01). Further analysis revealed no significant difference in the mean values of the indices of obesity between those with and without hypertension.

**Table 2 Distribution of Participants by BMI Categories and Gender**

<table>
<thead>
<tr>
<th>BMI Categories</th>
<th>Male (%)</th>
<th>Female (%)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>7(7.2)</td>
<td>3(2.4)</td>
<td>10(4.5)</td>
</tr>
<tr>
<td>Normal</td>
<td>35(36.1)</td>
<td>37(30.1)</td>
<td>72(32.7)</td>
</tr>
<tr>
<td>Overweight</td>
<td>33(34.0)</td>
<td>45(36.6)</td>
<td>78(35.5)</td>
</tr>
<tr>
<td>Obese</td>
<td>22(22.7)</td>
<td>38(30.9)</td>
<td>60(27.4)</td>
</tr>
<tr>
<td>Grade I</td>
<td>19(19.6)</td>
<td>19(15.4)</td>
<td>38(17.3)</td>
</tr>
<tr>
<td>Grade II</td>
<td>2(2.1)</td>
<td>11(8.9)</td>
<td>13(8.9)</td>
</tr>
<tr>
<td>Grade III</td>
<td>0(0)</td>
<td>7(7.2)</td>
<td>7(3.2)</td>
</tr>
</tbody>
</table>

**Note:** BMI (Kg/m²).

**Discussion**

In the present study, we determined the phenotypic pattern of obesity in a cohort of patients with type 2 diabetes attending the Diabetes clinic of Aminu Kano Teaching Hospital, Kano, Northwestern Nigeria. There were more females than males in our studied sample, a finding that is in tandem with the observation by Ogbera et al15 in Lagos, Southwest Nigeria. However, Isezu and Ezunu16 from Sokoto in the Northwestern part of the country reported a preponderance of males in their study. More women than men in our setting seek medical attention. Other studies have, however, reported higher proportion of males than females among their patients with type 2 diabetes.16,17

Generalized obesity, as measured by BMI, has been established as an independent risk factor for type 2 diabetes.18 In this study, we found the prevalence of generalized obesity to be 27.4% which is higher than the corresponding figure reported by Bakari and Onyemelukwe6 in a study among patients with type 2 diabetes in Zaria, Northwestern Nigeria and the 24.5% reported from a study in Sudan.33 The prevalence rates of overweight in the index study (35.5%) and the study from Zaria (35.0%) were however similar. Obesity in our study was more prevalent among women compared with men. Other studies, in patients with and without diabetes, have reported similar gender disparity in the prevalence of obesity.6,19,20 The higher obesity rate among females is attributed to short intervals between pregnancies, hormonal imbalance related to menopause, use of oral contraceptive pills, dietary habit and sedentary lifestyle.19

We found the mean values of WC and WhtR to be significantly higher among patients with generalized obesity compared with non-obese patients in this study. The positive and significant correlation between BMI and both WC and WhtR may explain this observation. We detected central obesity (defined by WC) in 50.9% of our study participants. This is lower than the 91.7% reported by Fasanmade and Okubadejo21 from Lagos Southwestern Nigeria, and the 72% reported by Unadike et al8 from

**Figure 1 Central adiposity among patients with T2DM by gender.**

**Abbreviations:** BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WhtR, waist to height ratio.
Uyo, in the South-South geopolitical zone of the country. These findings reflect regional differences in obesity rates across Nigeria. Possible reasons for these differences include the slender and taller stature of the northerners, occupational differences, as well as cultural attitudes to affluence and desire for weight gain, especially among women for marital purposes.

The prevalence of central obesity defined by WHR in our study is higher than that reported by Olebu et al from Enugu, Southeastern Nigeria, but lower than the rate reported from the northwestern city of Zaria. The mean WHR in the latter study was higher than in our study. In addition, the study from Zaria had more men than women, which is in contrast with the index study. WHR derives from two body circumferences (WC and HC), the presence of larger mean HC in women than men in our study may be responsible for the lower mean WHR among our study participants and by extension the lower prevalence of central obesity defined by WHR.

WC is increasingly being accepted as the best anthropometric indicator of abdominal adiposity and cardiometabolic risk. Other studies have, however, proved that WhtR is a better predictor of cardiovascular risk than any other anthropometric measurement including WC, WHR, BMI and skin-fold thickness. Yet few studies have used WhtR to assess central obesity among patients with type 2 diabetes. The prevalence of central obesity, measured by WhtR in this study (81.4%), is higher than the 52% found in a study among Bangladeshi adults with type 2 diabetes. The mean WhtR in our study is higher than that of the study from Bangladesh, which may explain the higher prevalence in the index study. There were more females with central obesity (using WhtR) than males in our study. Sousa et al reported similar findings among healthy Brazilian adults.

The prevalence of hypertension in this study (27%) is higher than the 19% reported by Mogre et al among patients with type 2 diabetes in Tamale, Ghana, but lower than the 54.2% among patients with diabetes from Benin City, Nigeria. Studies from Cameroon and Kenya also reported higher prevalence of hypertension at 66.4% and 50%, respectively. Differences in the prevalence of hypertension may be due to variations in definitions of hypertension, population characteristics and ethnicity. The limitations of our study include its cross-sectional design and the relatively small sample size employed. The latter makes generalization of our findings difficult.

Conclusion
The prevalence of obesity in our cohort of patients with type 2 diabetes is high. The predominant form of obesity among our patients was central obesity, which was most prevalent when indexed by WHR. The WhtR was as good as the WHR, but fared better than WC in detecting central obesity in our patients.

Acknowledgment
We thank the Clinical Assistants at the Diabetes clinic of Aminu Kano Teaching Hospital, Kano, for ensuring orderliness during data collection.

Disclosure
The authors report no conflicts of interest in this work.

References


Dovepress

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed journal covering the pathogenesis, diagnosis, management and prevention of diabetes, obesity and related metabolic disorders.

Dovepress

submit your manuscript | www.dovepress.com
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12
2789


